Loading...
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial.
Parker, C Coleman, R Sartor, O Vogelzang, N Bottomley, D Heinrich, D Helle, S O'Sullivan, J Fosså, S Chodacki, A
Parker, C
Coleman, R
Sartor, O
Vogelzang, N
Bottomley, D
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Citations
Altmetric:
Abstract
In Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA) trial, radium-223 versus placebo prolonged overall survival with favorable safety in castration-resistant prostate cancer patients with symptomatic bone metastases. Long-term radium-223 monitoring underlies a comprehensive safety and risk/benefit assessment.
Authors
Parker, C
Coleman, R
Sartor, O
Vogelzang, N
Bottomley, D
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Seke, M
Widmark, A
Johannessen, D
Hoskin, P
James, N
Solberg, A
Syndikus, I
Kliment, J
Wedel, S
Boehmer, S
Dall'Oglio, M
Franzén, L
Bruland, O
Petrenciuc, O
Staudacher, K
Li, R
Nilsson, S
Coleman, R
Sartor, O
Vogelzang, N
Bottomley, D
Heinrich, D
Helle, S
O'Sullivan, J
Fosså, S
Chodacki, A
Wiechno, P
Logue, John P
Seke, M
Widmark, A
Johannessen, D
Hoskin, P
James, N
Solberg, A
Syndikus, I
Kliment, J
Wedel, S
Boehmer, S
Dall'Oglio, M
Franzén, L
Bruland, O
Petrenciuc, O
Staudacher, K
Li, R
Nilsson, S
Description
Date
2017-07-10
Publisher
Collections
Files
Keywords
Type
Article
Citation
Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized Alpharadin in symptomatic prostate cancer trial. 2017 Eur Urol